Why Menopause Causes Hair Loss
Oestrogen and progesterone help maintain the hair growth cycle — extending the anagen (growth) phase and suppressing the effects of androgens on scalp follicles. As oestrogen levels decline during perimenopause and menopause, this protective effect is reduced. The result is an increase in follicle sensitivity to DHT, leading to a pattern of diffuse thinning across the crown and midpart that may accelerate significantly in the years around menopause.
This is distinct from male-pattern baldness — female menopausal hair loss rarely produces the defined receding hairline seen in men, and the frontal hairline is usually preserved. The pattern is typically Ludwig-scale diffuse thinning.
Hormonal and Non-Hormonal Treatments
Before surgical options are considered, non-surgical treatments should be evaluated — many women achieve meaningful stabilisation and some improvement with appropriate medical management.
- Hormone Replacement Therapy (HRT): May slow or reverse hair loss in women whose loss is directly driven by oestrogen decline. The decision to use HRT involves broader health considerations and requires a gynaecologist or endocrinologist's assessment.
- Topical minoxidil (2–5%): The most evidence-supported topical treatment for female pattern hair loss. FDA-approved. Used daily, it can maintain density and produce modest regrowth. Cessation reverses any benefit.
- Oral spironolactone (low-dose): An anti-androgen used off-label in women. Reduces DHT effects. Requires prescription and monitoring.
- PRP therapy: Multiple sessions of scalp injections can support density maintenance. Moderate evidence; useful as an adjunct.
- Nutritional support: Iron deficiency is frequently associated with diffuse hair loss in women. A full panel including ferritin, thyroid function (TSH) and vitamins should be checked before any treatment is initiated.
When Is Haartransplantation Appropriate After Menopause?
Hair transplant surgery can be appropriate for women with menopause-related hair loss under specific conditions. These include: loss that has stabilised on medical management, adequate donor density at the back and sides, specific pattern of loss (hairline recession, traction zones, defined bald areas rather than diffuse thinning), and realistic expectations.
Diffuse thinning across the entire scalp — without a clear stable pattern — is challenging to treat surgically because the donor zone may also be affected. Dr. Arslan assesses each case individually. Women with established, stable traction alopecia or hairline recession following menopause can be excellent candidates for FUE or DHI surgery.
The Assessment Process for Women
The assessment protocol for female patients differs from male AGA cases. Dr. Arslan's review includes: photographic analysis of the loss pattern, evaluation of donor zone density and quality, discussion of medical and hormonal history, and a frank conversation about surgical vs non-surgical paths. See our packages and pricing → for more information.
